Journal of Leukemia & Lymphoma 2022;31(1):16-19

doi:10.3760/cma.j.cn115356-20211206-00284

Progress in the treatment of relapsed/refractory follicular lymphoma

Zhijuan LIN 1 ; Bing XU

Affiliations

+expand

Keywords

Lymphoma, follicular; Recurrence; Refractory; Molecular targeted therapy; Antibodies, bispecific; Chimeric antigen receptor T-cell

Country

China

Language

Chinese

Abstract

Follicular lymphoma (FL) is the most common indolent B-cell lymphoma. Although patients with FL generally have a good prognosis, the treatment of relapsed/refractory FL remains a challenge. The 63rd American Society of Hematology (ASH) Annual Meeting announced the latest updates on relapsed/refractory FL, including the usage of targeted therapy, bio-specific antibodies and chimeric antigen receptor T-cell (CAR-T) therapy. This article provides an overview of the updates in combination with the reports presented at the ASH Annual Meeting.